1-3 of 3
Jake Shortt, FRACP, FRCPA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Naranie Shanmuganathan, MBBS FRACP FRCPA, Andrew Grigg, Ilona Cunningham, MBBS FRACP FRCPA, Jake Shortt, FRACP,FRCPA,PhD, Philip Rowling, MBBS FRACP FRCPA, John Reynolds, PhD, Rosemary Anne Harrup, MBBS, FRACP, FRCPA, David M Ross, MD PhD, David Kipp, MBBS,FRCPA,FRACP, Anthony K Mills, FRACP, FRCPA, MBBS, Christopher K Arthur, MBBS FRACP FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Kathryn Jackson, MBBS FRACP FRCPA, Nicholas Viiala, MBBS FRACP FRCPA, Robert Weinkove, MD, Agnes S. M. Yong, MD PhD, Deborah L. White, PhD FFSc (RCPA), Susan Branford, PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, On Behalf of the ALLG
Journal: Blood
Blood (2019) 134 (Supplement_1): 2926.
https://doi.org/10.1182/blood-2019-125740
Published: 2019
Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Andrew P. Grigg, MBBS, FRACP, FRCPA, MD, Naranie Shanmuganathan, MBBS, Ilona Cunningham, MBBS FRACP FRCPA, Jake Shortt, FRACP,FRCPA,PhD, Philip Rowling, MBBS FRACP FRCPA, John Reynolds, PhD, Rachel Cushion, Rosemary Anne Harrup, MD, David M Ross, David Kipp, MBBS,FRCPA,FRACP, Anthony K Mills, FRACP, FRCPA, MBBS, Christopher K Arthur, Anthony P Schwarer, MD MBBS(Hons), FRACP, FRCPA, Kathryn Jackson, MBBS FRACP, FRCPA, Nicholas Viiala, MBBS, FRACP, FRCPA, Robert Weinkove, MA, MBBS, PhD, FRCPath, FRACP, Agnes S. M. Yong, MD, PhD, Deborah L White, PhD, Susan Branford, PhD, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA, On Behalf of the ALLG
Journal: Blood
Blood (2018) 132 (Supplement 1): 459.
https://doi.org/10.1182/blood-2018-99-110569
Published: 2018
Journal Articles

N-Methyl-2-Pyrrolidone Is a Biologically Active Thalidomide Subunit with In Vivo anti-Myeloma Properties

Jake Shortt, FRACP, FRCPA, Andy Hsu, PhD, Geoffrey M Matthews, PhD, Marta Chesi, P.Leif Bergsagel, MD, Grant A. McArthur, MD, PhD, FRACP, MBBS, Paul Neeson, PhD, David Ritchie, MBBS, FRACP, FRCPA, Ricky W Johnstone, PhD
Journal: Blood
Blood (2010) 116 (21): 4082.
https://doi.org/10.1182/blood.V116.21.4082.4082
Published: 2010